Cargando…

Trends in hospital presentations following analytically confirmed synthetic cannabinoid receptor agonist exposure before and after implementation of the 2016 UK Psychoactive Substances Act

BACKGROUND AND AIMS: The United Kingdom (UK) Psychoactive Substances Act (PSA), implemented on the 26(th) May 2016, made the production, supply and sale of all non‐exempted psychoactive substances illegal. The aim of this study was to measure trends in hospital presentations for severe toxicity foll...

Descripción completa

Detalles Bibliográficos
Autores principales:	Craft, Sam, Dunn, Michael, Vidler, Dan, Officer, Jane, Blagbrough, Ian S., Pudney, Christopher R., Henderson, Graeme, Abouzeid, Ahmed, Dargan, Paul I., Eddleston, Michael, Cooper, Jamie, Hill, Simon L., Roper, Clair, Freeman, Tom P., Thomas, Simon H. L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9796520/ https://www.ncbi.nlm.nih.gov/pubmed/35665553 http://dx.doi.org/10.1111/add.15967

Ejemplares similares

Synthetic Cannabinoid Receptor Agonists Detection Using Fluorescence Spectral Fingerprinting
por: May, Benedict, et al.
Publicado: (2019)

Photochemical Fingerprinting Is a Sensitive Probe for the Detection of Synthetic Cannabinoid Receptor Agonists; toward Robust Point-of-Care Detection
por: Andrews, Rachael C., et al.
Publicado: (2023)

Identification of the synthetic cannabinoid‐type new psychoactive substance, CH‐PIACA, in seized material
por: Pasin, Daniel, et al.
Publicado: (2022)

ANALYTICALLY CONFIRMED PRESENCE OF PSYCHOACTIVE SUBSTANCES, ESPECIALLY NEW PSYCHOACTIVE SUBSTANCES IN A GROUP OF PATIENTS HOSPITALIZED WITH MENTAL AND BEHAVIOURAL DISORDERS DUE TO THE USE OF PSYCHOACTIVE SUBSTANCES DIAGNOSIS
por: Engelgardt, Piotr, et al.
Publicado: (2022)

Understanding Cannabinoid Psychoactivity with Mouse Genetic Models
por: Mackie, Ken
Publicado: (2007)

Chromatography as Method for Analytical Confirmation of Paracetamol in Postmortem Material Together with Psychoactive Substances
por: Biscevic-Tokic, Jasmina, et al.
Publicado: (2015)

Clinical withdrawal symptom profile of synthetic cannabinoid receptor agonists and comparison of effects with high potency cannabis
por: Craft, Sam, et al.
Publicado: (2021)

Transition-based reweighting and neural rational inference analysis of effects of new psychoactive substances on cannabinoid receptors
por: Dutta, Soumajit, et al.
Publicado: (2023)

In Vitro Model of Neuroinflammation: Efficacy of Cannabigerol, a Non-Psychoactive Cannabinoid
por: Gugliandolo, Agnese, et al.
Publicado: (2018)

Uncovering the psychoactivity of a cannabinoid from liverworts associated with a legal high
por: Chicca, A., et al.
Publicado: (2018)

Misuse of prescription medicines is as prevalent as the use of recreational drugs and novel psychoactive substances in Singapore: an unrecognised public health issue?
por: Chan, Wui Ling, et al.
Publicado: (2020)

In Silico Investigations into the Selectivity of Psychoactive and New Psychoactive Substances in Monoamine Transporters
por: Botha, Michelle J., et al.
Publicado: (2022)

Cannabidiol and Other Non-Psychoactive Cannabinoids for Prevention and Treatment of Gastrointestinal Disorders: Useful Nutraceuticals?
por: Martínez, Vicente, et al.
Publicado: (2020)

Non-Psychoactive Cannabinoid Modulation of Nociception and Inflammation Associated with a Rat Model of Pulpitis
por: Laks, Elana Y., et al.
Publicado: (2023)

Anti-inflammatory and antinociceptive effects of the selective cannabinoid CB(2) receptor agonist ABK5
por: Tang, Yaliang, et al.
Publicado: (2020)

Instant Detection of Synthetic Cannabinoids on Physical Matrices, Implemented on a Low-Cost, Ultraportable Device
por: Cozier, Gyles E., et al.
Publicado: (2023)

Novel Psychoactive Substances: The Razor’s Edge between Therapeutical Potential and Psychoactive Recreational Misuse
por: Correia, Beatriz, et al.
Publicado: (2022)

Novel Psychoactive Substances and Behavioral Addictions
por: Martinotti, Giovanni, et al.
Publicado: (2014)

Editorial: Pharmacology of new psychoactive substances
por: Lutfy, K., et al.
Publicado: (2023)

Cannabidiol, a non-psychoactive cannabinoid, leads to EGR2-dependent anergy in activated encephalitogenic T cells
por: Kozela, Ewa, et al.
Publicado: (2015)

Validation of a Bioanalytical Method for the Determination of Synthetic and Natural Cannabinoids (New Psychoactive Substances) in Oral Fluid Samples by Means of HPLC-MS/MS
por: Calò, Luca, et al.
Publicado: (2020)

Response to the letter from Wong et al.
por: Dear, James W., et al.
Publicado: (2019)

Psychoactive substances and the political ecology of mental distress
por: Aggarwal, Sunil K, et al.
Publicado: (2012)

PSYCHOACTIVE SUBSTANCE USE AMONG MEDICAL STUDENTS
por: Ali, R.V. Zulfikar, et al.
Publicado: (1994)

Banning Psychoactive Substances: A Slippery Slope
Publicado: (2015)

Priapism associated with novel psychoactive substance abuse
por: Jones, Patrick, et al.
Publicado: (2015)

An Expanding World of Novel Psychoactive Substances: Opioids
por: Zawilska, Jolanta B.
Publicado: (2017)

Experimentation with psychoactive substances by public school students
por: de Andrade, Maria Eliane, et al.
Publicado: (2017)

New Psychoactive Substances: A Matter of Time
por: Pantano, Flaminia, et al.
Publicado: (2019)

New psychoactive substances: a review and updates
por: Shafi, Abu, et al.
Publicado: (2020)

Psychoactive Substances Taken with Mephedrone and HCV Infection
por: Ordak, Michal, et al.
Publicado: (2021)

Molecular Insights on New Psychoactive Substances (NPSs)
por: Busardò, Francesco Paolo, et al.
Publicado: (2022)

An Update on Psychoactive Substances: Pharmacology and Toxicology Issues
por: Chiappini, Stefania, et al.
Publicado: (2023)

Genotoxicity Evaluation of The Novel Psychoactive Substance MTTA
por: Lenzi, Monia, et al.
Publicado: (2023)

Disruption of hippocampal synaptic transmission and long‐term potentiation by psychoactive synthetic cannabinoid ‘Spice’ compounds: comparison with Δ(9)‐tetrahydrocannabinol
por: Hoffman, Alexander F., et al.
Publicado: (2016)

Deaths from novel psychoactive substances in England, Wales and Northern Ireland: Evaluating the impact of the UK psychoactive substances act 2016
por: Deen, Adrian A, et al.
Publicado: (2021)

Exploring determinants of agonist efficacy at the CB1 cannabinoid receptor: Analogues of the synthetic cannabinoid receptor agonist EG‐018
por: Finlay, David B., et al.
Publicado: (2022)

A Case of Status Epilepticus and Transient Stress Cardiomyopathy Associated with Smoking the Synthetic Psychoactive Cannabinoid, UR-144
por: Fawaz, Sarah Al, et al.
Publicado: (2019)

Cannabinoids: A New Group of Agonists of PPARs
por: Sun, Yan, et al.
Publicado: (2007)

Awareness of users and motivational factors for using new psychoactive substances in Belgium
por: Simonis, Sarah, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_6g6u9pu0lj3166538aumi057ui